Baird raised the firm’s price target on Axsome Therapeutics (AXSM) to $241 from $209 and keeps an Outperform rating on the shares. The firm updated its model following the FDA approval of label expansion for Auvelity in Alzheimer’s agitation.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $250 from $220 at Oppenheimer
- Axsome Therapeutics price target raised to $281 from $245 at Deutsche Bank
- Axsome Wins FDA Nod for Alzheimer’s Agitation Drug
- Axsome Therapeutics price target raised to $217 from $207 at Morgan Stanley
- Axsome Therapeutics given ‘clean label’ for Auvelity in ADA, says TD Cowen